title: Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer.
abstract: BACKGROUND
  Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease.
  
  
  METHODS
  Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed.
  
  
  RESULTS
  Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group.
  
  
  CONCLUSIONS
  Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.
authors: Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia. adnan.khattak@health.sa.gov.au
authors: Muhammad A
authors: MA
authors: Khattak
authors: Hilary L
authors: HL
authors: Martin
authors: Carol
authors: C
authors: Beeke
authors: Timothy
authors: T
authors: Price
authors: Scott
authors: S
authors: Carruthers
authors: Susan
authors: S
authors: Kim
authors: Robert
authors: R
authors: Padbury
authors: Christos S
authors: CS
authors: Karapetis
mesh_terms: D001859:Bone Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D001932:Brain Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D015179:Colorectal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D010386:Pelvic Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D011379:Prognosis; D015996:Survival Rate